000 | 01728 a2200505 4500 | ||
---|---|---|---|
005 | 20250515060206.0 | ||
264 | 0 | _c20070628 | |
008 | 200706s 0 0 eng d | ||
022 | _a0923-7534 | ||
024 | 7 |
_a10.1093/annonc/mdl495 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aCalvo, E | |
245 | 0 | 0 |
_aAssessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. _h[electronic resource] |
260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2007 |
||
300 |
_a761-7 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xchemistry |
650 | 0 | 4 |
_aCyclin-Dependent Kinase Inhibitor p27 _xanalysis |
650 | 0 | 4 |
_aErbB Receptors _xanalysis |
650 | 0 | 4 | _aErlotinib Hydrochloride |
650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xanalysis |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHead and Neck Neoplasms _xchemistry |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunohistochemistry |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aQuinazolines _xadverse effects |
650 | 0 | 4 |
_aSkin _xdrug effects |
700 | 1 | _aMalik, S N | |
700 | 1 | _aSiu, L L | |
700 | 1 | _aBaillargeon, G M | |
700 | 1 | _aIrish, J | |
700 | 1 | _aChin, S F | |
700 | 1 | _aSantabarbara, P | |
700 | 1 | _aKreisberg, J I | |
700 | 1 | _aRowinsky, E K | |
700 | 1 | _aHidalgo, M | |
773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 18 _gno. 4 _gp. 761-7 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdl495 _zAvailable from publisher's website |
999 |
_c16875892 _d16875892 |